Sunday, December 06, 2020 11:25:57 AM
It is not only moral fraud--it is also an intellectual fraud on a grand scale; IT IS regrettable that we all deceive ourselves into believing anything for convenience but to deceive others betrays a moral bankruptcy that society should not tolerate because it costs peoples their lives--it would be like me prescribing Vascepa, then handing out placebos at the pharmacy, and pocketing the patient's money.
You can game the system and pass the musicians exam ( I have 7 board certifications so I know a thing or two about gaming exams) but I could never pass myself off as an expert just an informed dilettante).
Passed the music exam but NOT a true musician
Gen V but NOT Vascepa
Pharmaceutical equivalence but NOT therapeutic biological equivalence
We do have a moral duty to speak the Truth.
I feel uplifted after stating that.
HK
Interesting though how their honors, the Law lords led by Judge Prost and all the Obama era appointed acolytes are very keen to display their political loyalty as a badge of honor, and shore up H-W for the "public good" and yet so easily forget all the basic principles of justice; truth and equanimity under the Law. Prost et al should reread Berry's third principle of Jurisprudence before she rushes to bring together the CAFC and rubber stamp Teva's en banc to reinstate Teva vs. West Ward over Teva vs GSK, to re-establish dominant case precedence:
Rome burns while SCOTUS fiddles.
HK
You can game the system and pass the musicians exam ( I have 7 board certifications so I know a thing or two about gaming exams) but I could never pass myself off as an expert just an informed dilettante).
Passed the music exam but NOT a true musician
Gen V but NOT Vascepa
Pharmaceutical equivalence but NOT therapeutic biological equivalence
We do have a moral duty to speak the Truth.
I feel uplifted after stating that.
HK
Interesting though how their honors, the Law lords led by Judge Prost and all the Obama era appointed acolytes are very keen to display their political loyalty as a badge of honor, and shore up H-W for the "public good" and yet so easily forget all the basic principles of justice; truth and equanimity under the Law. Prost et al should reread Berry's third principle of Jurisprudence before she rushes to bring together the CAFC and rubber stamp Teva's en banc to reinstate Teva vs. West Ward over Teva vs GSK, to re-establish dominant case precedence:
The universe is composed of subjects to be communed with, not objects to be used. As a subject, each component of the universe is capable of having rights. Thomas Berry
Rome burns while SCOTUS fiddles.
HK
Recent AMRN News
- Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026 • GlobeNewswire Inc. • 04/15/2026 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
